BioNTech SE (BNTX) Down 5.0% — Is This the Moment to Unload?
BioNTech SE (BNTX) came under pressure this Thursday, closing at $86.12 on the NASDAQ — a $4.58 decline from the prior close of $90.70. The loss leaves the stock roughly 30.5% below its 52-week high of $124.00, reached on January 22, 2026. Shares now sit only about 8.3% above the 52-week low of $79.52. With most of the year's gains erased, the stock is drifting back toward the bottom of its range.
Volume came in at 1,176,547 shares, slightly above the 90-day average of 1,128,978. Turnover was essentially in line with normal activity, which points to steady selling rather than a disorderly exit.
Why BioNTech SE Price is Moving Lower
The most plausible driver of Thursday's decline was a broad biotech selloff. The SPDR S&P Biotech ETF (XBI) fell about 3% during the session. Vaccine peer Novavax (NVAX) dropped about 4% even after raising its revenue outlook, which shows how little company-specific good news counted for in this tape. Within the Health Care peer group, Moderna, Inc. (MRNA) fell 6.55% and Revolution Medicines, Inc. (RVMD) slid 11.04%. That puts BioNTech's 5.05% decline squarely in line with the rest of the group. BNTX fell harder than the ETF, which suggests investors are also taking a more cautious view of the company's outlook following its latest results.
That reassessment centers on the quality of BioNTech's Q3 report, released on November 3. On the surface, the numbers were strong. Adjusted EPS came in at $1.76 against a $0.78 consensus estimate. Revenue reached €1.289 billion, ahead of expectations near €1.012 billion. IFRS net profit was €184.5 million, compared with a €28.7 million loss a year earlier. Underneath the beat, however, revenue fell 15% year over year as COVID-vaccine demand continued to weaken. Of the quarter's revenue, €613 million came from the company's Bristol Myers Squibb (BMY) partnership, which makes the result look more dependent on partnership economics than on a recovering commercial base.
Management raised the low end of its 2026 revenue guidance from €1.6 billion to €1.7 billion. It held the upper end at €1.9 billion, a narrower range but not a materially higher ceiling. Analyst sentiment cooled the day after the report. On November 4, Morgan Stanley cut its price target from $114 to $106 while keeping its Overweight rating. Taken together, the sector-wide selling, the shrinking year-over-year revenue, and a lower price target from a supportive analyst explain why the earnings beat failed to hold the stock up.
What is the BioNTech SE Rating - Should I Sell?
Weiss Ratings assigns BNTX a D- rating. The rating was upgraded on 10/2/2025. Current recommendation is Sell. The upgrade moved BioNTech off the very bottom of the scale. A D- still signals a risk/reward profile that does not support ownership, as a company transitions from pandemic-era windfall revenue to an oncology pipeline that has yet to generate meaningful commercial sales.
The balance sheet is the clear bright spot. BioNTech is rated Excellent on the Solvency Index, reflecting financial reserves built during the peak years of COVID-vaccine sales. That cushion lets the company fund a broad roster of Phase II and Phase III oncology programs without immediate dependence on capital markets. It is the main reason the rating is not lower. A company burning this much on research with a weaker balance sheet would face far more acute pressure.
Where the picture deteriorates is in the operating and market-based measures. The Weak rating on the Growth Index reflects a 58.50% revenue contraction, which is the steep unwinding of the vaccine franchise that the 15% year-over-year decline in the third quarter shows is still underway. The Very Weak rating on the Efficiency Index is backed by a -63.54% profit margin and trailing EPS of -$7.82. A forward P/E of -11.11 indicates that losses are expected to continue. One profitable quarter driven by partnership revenue does not yet change that trajectory. The Weak ratings on the Total Return Index and the Volatility Index reflect what shareholders have actually experienced. The stock trades about 30.5% below its January high, and Thursday's 5.05% drop in step with a sector-wide biotech selloff shows how exposed the shares remain to swings in group sentiment.
Within the Health Care sector, BioNTech sits alongside Moderna, Inc. (MRNA, D-), its closest mRNA counterpart, and Revolution Medicines, Inc. (RVMD, D-). It trails Zoetis Inc. (ZTS, D) and IQVIA Holdings Inc. (IQV, D+), both of which carry modestly better profiles in Weiss's framework. None of these comparisons offer much reassurance, since the group as a whole sits in Sell territory.
About BioNTech SE
BioNTech SE (BNTX) is a Health Care company headquartered in Mainz, Germany, and incorporated in 2008. The company develops and commercializes immunotherapies. It is best known for BNT162, its mRNA vaccine against the SARS-CoV-2 virus, which became one of the most widely distributed COVID-19 vaccines in the world. Revenue from that franchise funded a rapid expansion of the company's research operations and established its expertise in mRNA technology.
The company's long-term strategy now rests on oncology. Its late-stage pipeline includes gotistobart in Phase III for metastatic non-small cell lung cancer, and pumitamig in Phase III for small cell lung cancer and advanced or metastatic triple-negative breast cancer. Trastuzumab pamirtecan is also in Phase III for metastatic breast cancer. Pumitamig is in further Phase II testing across a wide range of tumor types, from glioblastoma and hepatocellular carcinoma to metastatic pancreatic ductal adenocarcinoma, and in Phase 2/3 work for colorectal and non-small cell lung cancer. BNT113 is in Phase 2/3 development for HPV-positive head and neck squamous cell carcinoma. Earlier-stage oncology candidates include BNT116 for non-small cell lung cancer, BNT326/YL202 for multiple solid tumors, and autogene cevumeran, an individualized therapy being studied in colorectal cancer.
BioNTech also keeps an infectious disease portfolio. This includes BNT166 for mpox, BNT164 for tuberculosis, BNT165 for malaria, and a combination SARS-CoV-2 and influenza candidate pairing BNT162 with BNT161. The company's competitive advantages lie in its mRNA platform, its manufacturing know-how, and partnerships with large pharmaceutical companies such as Bristol Myers Squibb that bring both capital and commercial reach. The breadth of the pipeline spreads clinical risk across many programs. The business will remain dependent on clinical readouts and regulatory decisions until one or more oncology assets reach the market at scale.
Investor Outlook
BioNTech SE (BNTX) carries a Weiss Rating of D- (Sell), and the combination of falling vaccine revenue, persistent losses, and heavy sensitivity to biotech sector swings argues for caution despite the company's strong balance sheet. Investors should watch whether 2026 revenue lands within the €1.7 billion to €1.9 billion guidance range, how much future results depend on partnership income, and whether late-stage oncology readouts for gotistobart and pumitamig give the stock a catalyst beyond its COVID legacy. See full rankings of all D- rated Health Care stocks inside the Weiss Stock Screener.
--